Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176040 | PMC |
| http://dx.doi.org/10.1016/j.jdcr.2018.09.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ocrelizumab-induced vulvovaginal pyoderma gangrenosum in a patient with relapsing-remitting multiple sclerosis.
JAAD Case Rep
October 2022
Department of Dermatology, University Medical Center of the Johannes-Gutenberg University Mainz, Mainz, Germany.
Vulvovaginal Pyoderma Gangrenosum in a Patient Treated With Ocrelizumab for Multiple Sclerosis.
J Low Genit Tract Dis
April 2022
Department of Dermatology, Columbia University Irving Medical Center, New York, NY.
Inflammatory vaginitis in women on long-term rituximab treatment for autoimmune disorders.
BMC Womens Health
August 2021
Department of Obstetrics and Gynecology, Vincent Center for Reproductive Biology, Massachusetts General Hospital, 55 Fruit St, Boston, MA, 02114, USA.
Background: Consequences of long-term B cell depletion with rituximab are not well understood. We describe inflammatory vaginitis as a potential side effect of long-term rituximab treatment, distinct from previously described vulvovaginal pyoderma gangrenosum.
Methods: We performed a retrospective analysis of women treated with rituximab for more than 1 year to determine the prevalence and clinical characteristics of vaginitis cases.
Vulvovaginal pyoderma gangrenosum associated with rituximab use in 2 patients with rheumatoid arthritis.
JAAD Case Rep
April 2021
Department of Dermatology, Marshfield Clinic Health System, Marshfield, Wisconsin.
A case of rituximab-induced pyoderma gangrenosum.
JAAD Case Rep
November 2018
Schulich School of Medicine and Dentistry, London, Canada.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!